{"task_id": "2939c904260f77d7", "source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 226/464)", "text": "laparoscopy, staging laparotomy\nOvarian Cancer\n215\n\n--- Page 237 ---\nDIAGNOSTIC AND PROGNOSTIC ISSUES\nDISTINGUISHING FEATURES BETWEEN OVARIAN\nCANCER AND BENIGN CYSTS\nany of the following\nfeatures should prompt consideration of ovarian can\ncer and biopsy: any postmenopausal women, >8 cm\nin premenopausal women, solid, or cystic but still\npresent after 2 months of oral contraceptive pills,\npresence of ascites\nADVERSE\nPROGNOSTIC\nFACTORS\nadvanced\nstage, high grade, residual disease after debulking\n(38 vs. 60 months), poor performance status\nRelated Topics\nBRCA Mutations (p. 225)\nCancer Screening (p. 222)\nTumor Markers (p. 220)\nMANAGEMENT\nEPITHELIAL OVARIAN TUMORS\n\u0002\nSTAGE IA B, GRADE 1\ntotal abdominal hysterect\nomy/bilateral salpingo oophorectomy (TAH/BSO).\nIf premenopausal, consider unilateral oophorect\nomy to preserve fertility until childbearing is\ncompleted\n\u0002\nSTAGE IA B GRADE 2\u20133, IC, II\nTAH/BSO, adjuvant\nchemotherapy (carboplatin paclitaxel \u00036)\n\u0002\nSTAGE III\ndebulking, retroperitoneal lymph node\ndissection, plus adjuvant chemotherapy (if optimal\ndebulking with residual disease <1 cm, consider\nintraperitoneal\nchemotherapy\nor\ncarboplatin\npaclitaxel \u00036; if suboptimal debulking, consider\ncarboplatin paclitaxel \u00036). For those who derived\na complete response to carboplatin and paclitaxel,\nconsolidation chemotherapy with 12 cycles of\npaclitaxel may be considered\n\u0002\nSTAGE\nIV\nfirst line\npalliative\nchemotherapy\nincludes carboplatin paclitaxel \u00036. Second line\nchemotherapy includes ongoing doublet therapy\nMANAGEMENT (CONT\u2019D)\n(if greater than 6 months since last line of plati\nnum based therapy; regimens include carbopla\ntin paclitaxel, carboplatin liposomal doxorubicin,\nand carboplatin gemcitabine) or single agent\ntherapy using carboplatin, paclitaxel, cisplatin,\ntopotecan, etoposide, gemcitabine, vinorelbine,\nifosfamide, or liposomal doxorubicin. In plati\nnum resistant disease, single agent therapy is\nrecommended. Platinum resistance is commonly\ndefined as clinical evidence of disease progression\n<6 months from last platinum therapy\nGERM CELL TUMORS\nsurgery is mainstay. May\nconsider unilateral salphingo oophorectomy to pre\nserve fertility in young women. For advanced disease\nconsider BEP (bleomycin etoposide cisplatin) che\nmotherapy after surgery. The treatment paradigm\nis based entirely on germ cell tumors of the testicle\n(p. 212)\nSEX CORD STROMAL TUMORS\nsurgery is main\nstay. Excellent prognosis\nTREATMENT ISSUES\nOVARIAN CANCER SURGERY\nfor both staging\nand cytoreduction. Key features include (1) obtain\ning free fluid or lavage for cytology, (2) systematic\nexploration of all intra abdominal organs, surfaces\nand retroperitoneum for pelvic and paraaortic\nlymph nodes, (3) biopsy of any suspicious areas or\nrandom biopsies from peritoneum of the cul de sac,\nparacolic gutters, bladder, intestinal mesentery and\nlymph nodes, (4) biopsy of diaphragm, (5) resection\nof omentum, and (6) total abdominal hysterectomy\nand bilateral salpingo oophorectomy. For patients\nwho had a good response to neoadjuvant che\nmotherapy (no prior maximal surgical effort), surgi\ncal resection to remove residual macroscopic dis\nease is generally recommended\nEndometrial Cancer\nPATHOPHYSIOLOGY\nHISTOLOGIC TYPE OF UTERINE CANCER\n\u0002\nENDOMETRIAL CARCINOMAS (97%)\n\u0002\nADENOCARCINOMA (>95%)\n\u0002\nCLEAR CELL CARCINOMA\nassociated with more\naggressive disease and worse prognosis, but\nmore responsive to chemotherapy\n\u0002\nPAPILLARY SEROUS CARCINOMA\nassociated with\nmore aggressive disease and worse prognosis\nPATHOPHYSIOLOGY (CONT\u2019D)\n\u0002\nSMALL CELL CARCINOMA\n\u0002\nMALIGNANT MIXED MULLERIAN TUMORS\n\u0002\nUTERINE SARCOMA (3%)\nRISK FACTORS\n\u0002\nPERSONAL\nage, excess estrogen (early menarche,\nlate menopause, nulliparity, obesity with conver\nsion of androstenedione to estrone by aromatase\nin adipose tissue)\n216\nEndometrial Cancer", "text_length": 3803, "metadata": {"source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 226/464)", "type": "chunk", "chunk_index": 225, "total_chunks": 464, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T18:40:09.557706", "document_uuid": "fda2cab4-cdd9-4015-af24-46fd62c86d94", "filename": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf", "category": "medical_pdf", "section": "body", "year": null, "outdated": false, "document_id": "fda2cab4-cdd9-4015-af24-46fd62c86d94"}, "created_at": "2025-12-11T18:40:09.558792", "status": "complete", "chunks_added": 2}